Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
News about Charles River Laboratories International, Inc. (NYSE: CRL) focuses on its role in research and development in biotechnology and its activities as a contract research and manufacturing partner to pharmaceutical, biotechnology, government, and academic clients. Company updates often highlight how Charles River’s research models, discovery and safety assessment services, and manufacturing solutions support the discovery, early-stage development, and safe manufacture of new therapies.
Investors and industry followers can expect frequent news on strategic transactions and partnerships. Recent announcements include planned acquisitions such as K.F. (Cambodia) Ltd., a provider of non-human primates for regulatory-required biomedical, pharmaceutical, and toxicological research, and PathoQuest SAS, a provider of next-generation sequencing solutions for manufacturing quality-control testing. The company also reports collaborations, for example with The Francis Crick Institute on antibody-drug conjugate discovery and with X-Chem, Inc. to expand hit identification capabilities using DNA-encoded library technology.
Charles River’s news flow also covers scientific and operational initiatives. The company has announced the creation of a Scientific Advisory Board led by Dr. Namandjé N. Bumpus to advance New Approach Methodologies (NAMs) and reduce reliance on animal testing, as well as the expansion of its Cell & Gene Therapy Incubator Program to support early-stage advanced therapy developers and enabling technology companies. Updates on its strategic review, portfolio refinement, restructuring initiatives, and capital deployment plans provide additional context on long-term positioning and financial priorities.
Governance and leadership developments are another recurring theme, such as the planned CEO succession and the appointment of a Chief Scientific and Innovation Officer. Earnings releases and conference presentations offer insight into demand trends across the Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions segments. For readers tracking CRL, this news page brings together these earnings updates, transaction announcements, scientific collaborations, and strategic milestones in one place.
Charles River Laboratories (NYSE: CRL) and ASC Therapeutics have expanded their partnership to manufacture ASC618, a second-generation gene therapy targeting hemophilia A. This collaboration leverages Charles River's expertise in Good Manufacturing Practice (GMP) for virus production established since 2019. ASC618 aims to deliver a modified version of the F8 gene to treat hemophilia A, following ASC Therapeutics' receipt of IND clearance and key regulatory designations in the U.S. and Europe. The partnership underscores a strong relationship built on trust and shared objectives for therapeutic development.
Charles River Laboratories (NYSE: CRL) will present at the Jefferies Healthcare Conference on June 8 at 10:00 a.m. ET, and at the William Blair 42nd Annual Growth Stock Conference on June 9 at 10:40 a.m. CT (11:40 a.m. ET). The presentations will cover the company's strategic focus and recent business developments. Live webcasts will be available on the Investor Relations section of the Charles River website, with replays accessible for two weeks after each event.
Charles River supports drug development for biotech and pharmaceutical sectors globally.
Charles River Laboratories (CRL) reported a strong performance for Q1 2022, with revenues reaching $913.9 million, marking a 10.8% increase year-over-year. Adjusted earnings per share (EPS) stood at $2.75, up 8.7% from the previous year. Key growth was driven by acquisitions (4.7% contribution) and organic growth of 9.4%. However, revenue was negatively impacted by foreign currency translation and divestitures. The company updated its 2022 guidance, raising reported revenue growth expectations to 13.5% - 15.5%.
Charles River Laboratories (NYSE: CRL) and Valo Health have launched Logica™, an AI-powered drug discovery solution that combines biological insights with optimized preclinical assets. This integrated offering leverages Valo's Opal Computational Platform and Charles River's expertise to streamline drug discovery. Logica features Advanceable Lead (Logica-AL™) and Candidate (Logica-C™) programs, targeting a 90% success rate in lead series and delivering development candidates 58% of the time. The collaboration marks a significant step forward in drug development, focusing on client value generation.
Charles River Laboratories (CRL) will release its first-quarter 2022 financial results on May 4, before market opening. A conference call to discuss these results is scheduled for the same day at 9:30 a.m. ET. Investors can access the live webcast through the Investor Relations section on CRL's website. The company offers key products and services aimed at accelerating research and drug development for pharmaceutical and biotech sectors.
Charles River Laboratories International, Inc. (NYSE: CRL) has published its 2021 Corporate Citizenship Report, highlighting ESG commitments and initiatives. The report emphasizes leadership accountability, employee engagement through global Resource Groups, community investments, and significant reductions in greenhouse gas emissions. Notably, the company aims for 100% renewable electricity across facilities by 2023. The report adheres to SASB and GRI standards, showcasing Charles River's dedication to corporate responsibility.
Charles River Laboratories (CRL) has acquired Explora BioLabs for approximately $295 million in cash, enhancing its Charles River Accelerator and Development Lab (CRADL™) footprint. This acquisition adds over 15 vivarium facilities across key biohubs like Southern California, San Francisco, and Boston, with plans for expansion in Seattle. Explora BioLabs had an annual revenue of $38 million in 2021, with expected strong growth. The acquisition is projected to be slightly accretive to non-GAAP earnings per share starting in 2023.
Charles River Laboratories (NYSE: CRL) announced the appointment of Flavia H. Pease as the new Chief Financial Officer, effective April 25. She succeeds David R. Smith, who plans to retire. Pease brings over 20 years of experience from Johnson & Johnson, where she served as Vice President and Group CFO of the Medical Devices business, which generated annual revenues of $27 billion in 2021. She is expected to assume the CFO role after the filing of the Company’s 10-Q in early May 2022. Smith will transition to Senior Financial Advisor until February 2023.
Charles River Laboratories International, Inc. (NYSE: CRL) reported fourth-quarter revenue of $905.1 million, a 14.4% increase year-over-year, and full-year revenue of $3.54 billion. Fourth-quarter GAAP EPS was $2.67, a 5.0% decline, while non-GAAP EPS rose 4.2% to $2.49.
The company reaffirmed its 2022 guidance, anticipating low-teens revenue growth driven by robust client demand. Significant contributions came from the Manufacturing segment, with revenues rising 47.4% in Q4. Despite challenges including the RMS Japan divestiture, CRL's portfolio growth remains strong.
Charles River Laboratories (NYSE: CRL) has secured a wind energy contract with Repsol, aiming to meet all of its European electricity needs through renewable sources by 2023. This virtual power purchase agreement (VPPA) encompasses 30.5 megawatts of wind energy, equating to reduced carbon emissions from over 28,000 homes. This initiative aligns with Charles River's sustainability targets, which also include a solar contract in North America. Together, these efforts will contribute to 90% of the company’s global electricity being sourced from renewables by 2023.